<DOC>
	<DOCNO>NCT01425294</DOCNO>
	<brief_summary>This study post-authorisation pharmacoepidemiology study , commit Center Drug Evaluation ( CDE ) State Food Drug Administration ( SFDA ) , order provide efficacy safety data Faslodex 250mg real life clinical practice China . The objective post marketing study explore efficacy tolerability Fulvestrant ( FASLODEXâ„¢ ) 250 mg postmenopausal woman oestrogen receptor positive , locally advanced metastatic breast cancer disease relapse adjuvant anti-estrogen therapy disease progression therapy anti-estrogen .</brief_summary>
	<brief_title>Collection Efficacy Safety Data Chinese Patients Who Have Received Faslodex 250mg Treatment</brief_title>
	<detailed_description>A Multicenter , non-interventional , prospective study collect efficacy safety data Chinese patient receive Faslodex 250mg treatment condition actual usage clinical practice</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Chinese postmenopausal woman estrogen receptor positive , locally advanced metastatic breast cancer Failure previous antiestrogen therapy , already receive Faslodex 250mg treatment determine treat physician . The prescription Faslodex clearly separate decision include subject NIS , part normal medical practice . The recruitment patient study within 1 month first Faslodex injection . Provision subject inform consent . If participate control clinical trial , subject take part study . Hypersensitivity active substance , excipients . Pregnancy lactation , severe hepatic impairment .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chinese post-menopausal woman</keyword>
	<keyword>oestrogen receptor-positive locally advance</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>fulvestrant 250 mg</keyword>
	<keyword>failure adjuvant anti-oestrogen therapy</keyword>
</DOC>